A
Andrew G. Nicholson
Researcher at National Institutes of Health
Publications - 512
Citations - 87875
Andrew G. Nicholson is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lung cancer & Idiopathic pulmonary fibrosis. The author has an hindex of 113, co-authored 477 publications receiving 73860 citations. Previous affiliations of Andrew G. Nicholson include National Yang-Ming University & University College London.
Papers
More filters
Journal ArticleDOI
Non-small-cell lung cancer
Peter Goldstraw,David Ball,James R. Jett,Thierry Le Chevalier,Eric Lim,Andrew G. Nicholson,Frances A. Shepherd +6 more
TL;DR: Advances in treatment that have seen the introduction of a new generation of chemotherapy agents, a proven advantage to adjuvant chemotherapy after complete resection for specific stage groups, new techniques for the planning and administration of radiotherapy, and new surgical approaches to assess and reduce the risks of surgical treatment are described.
Journal ArticleDOI
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.
Athol U. Wells,Sujal R. Desai,Michael B. Rubens,Nicole S L Goh,Derek Cramer,Andrew G. Nicholson,Thomas V. Colby,Roland M. du Bois,David M. Hansell +8 more
TL;DR: In this paper, the composite physiologic index (CPI) most closely reflecting the morphologic extent of pulmonary fibrosis was identified as a more accurate prognostic determinant in usual interstitial pneumonia than an individual pulmonary function test.
Journal ArticleDOI
Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends
Panagiota Latsi,Roland M. du Bois,Andrew G. Nicholson,Thomas V. Colby,Danai Bisirtzoglou,Ageliki Nikolakopoulou,Srihari Veeraraghavan,David M. Hansell,Athol U. Wells +8 more
TL;DR: It is concluded that at 12 months, serial pulmonary function trends have considerable prognostic value in UIP and NSIP, while their histologic distinction provides no additional prognostic information when pulmonary function Trends are clear cut or when functional impairment is severe.
Journal ArticleDOI
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Ming-Sound Tsao,Keith M. Kerr,Mark M. Kockx,Mary Beth Beasley,Alain C. Borczuk,Johan Botling,Lukas Bubendorf,Lucian R. Chirieac,Gang Chen,Teh Ying Chou,Jin Haeng Chung,Sanja Dacic,Sylvie Lantuejoul,Mari Mino-Kenudson,Andre L. Moreira,Andrew G. Nicholson,Masayuki Noguchi,Giuseppe Pelosi,Claudia Poleri,Prudence A. Russell,Jennifer L. Sauter,Erik Thunnissen,Ignacio I. Wistuba,Hui Yu,Murry W. Wynes,Melania Pintilie,Yasushi Yatabe,Fred R. Hirsch +27 more
TL;DR: The Blueprint (BP) Programmed Death Ligand 1 (PD-L1) Immunohistochemistry Comparability Project is a pivotal academic/professional society and industrial collaboration to assess the feasibility of harmonizing the clinical use of five independently developed commercial PD-L 1 immunohistochemical assays.
Journal ArticleDOI
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.
William D. Travis,Elisabeth Brambilla,Masayuki Noguchi,Andrew G. Nicholson,Kim R. Geisinger,Yasushi Yatabe,Charles A. Powell,David G. Beer,G. J. Riely,Kavita Garg,John H. M. Austin,Valerie W. Rusch,Fred R. Hirsch,James R. Jett,Pan-Chyr Yang,Michael Gould +15 more
TL;DR: Non-small cell lung carcinomas (NSCLC), in patients with advanced stage disease, are to be classified into more specific types, such as adenocarcinoma or squamous cell carcinoma, whenever possible.